Drug Trial Radar · NCT07287137
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Nov 12, 2025
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Centers for Disease Control and Prevention; Food and Drug Administration (FDA)
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Conditions
- COVID -19
- COVID - 19
- COVID 19
- Influenza
- Respiratory Virus
- Respiratory Viruses
- Respiratory Virus Infection
- Respiratory Virus Infections
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccineDrug
COVID-19 Vaccine, mRNA
Novavax recombinant protein vaccineDrug
Recombinant protein vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Variant-specific immune responses (Year 2 Only)Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination, 30 days (+/- 10 days), and 150 days (+/- 10 days) after vaccination.
- Variant-specific immune responses (Year 1 Only)Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination and 30 days (+/- 10 days after vaccination).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Walter Reed National Military Medical Center
Bethesda, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.